**COUNTRY**

Optional: Please include here some basic figures: e.g. map of your country, total population, GDP per capita, organisation of the health care sector (e.g. if social health insurance system or tax funded system = NHS), health expenditure, pharmaceutical expenditure etc.

Logo country institution

Logo country institution

Name of institution(s) and contact details (telephone, email address)

**Pharmaceutical pricing and reimbursement policies**

Please include the following information on your poster (you may picture the path of a medicine along the value chain in your country – like a flowchart, see examples below)

Who are the competent authorities / decision making institutions for **pricing of medicines** in your country?

Are prices of medicines centrally (i.e. by the authorities) regulated in your country? Is there a difference between the outpatient and inpatient sectors OR public and private sectors?

* If regulated, how are prices of medicines set? (for which medicines – e.g. only for medicines included in the National Essential Medicine List – see below, prescription-only medicines, generics, biosimilars; at which price level (i.e. ex-factory price, wholesale price); pricing procedures (e.g. external price referencing, tendering, negotiations, central procurement, free pricing etc.)
* Is wholesale and pharmacy remuneration (e.g. margins) regulated? If yes, for which medicines and which form (e.g. linear or regressive)
* VAT on medicines? (standard rate and reduced rate for medicines and other relevant taxes?)

Pricing

of
medicines

Who are the competent authorities / decision making institutions for **coverage /reimbursement** of medicines in your country?

Are medicines covered by public funds? Is there a difference between the outpatient and inpatient sectors or public and private sectors?

* Which medicines?
* How: Positive / negative list / National Essential Medicine List / formulary / hospital formularies (individual or central)?
	+ number of medicines included on positive list
* Reference price system (RPS) of cluster of substitutable medicines:
	+ yes / no, design of the RPS (ATC level), since when
* Co-payments: prescription fees, deductibles, percentage co-payment, etc.
* Mechanisms for vulnerable groups?
* Does any national governmental disease program exist which includes coverage of specific medicines?

Coverage /

Reimbursement

**COVERAGE / REIMBURSEMENT**

**Recommendation:**

HTA

Optional: please describe if and how an HTA process is applied in the pharmaceutical pricing and reimbursement processes etc.

We would recommend you to present this information in form of a graph – please see the example of [Portugal](https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Portugal_0.pdf) (using Word or PowerPoint).
Further **country examples** are available at the [PPRI/WHOCC website](https://ppri.goeg.at/ppri_posters) or [here (examples of the 4th PPRI Conference 2019](https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/_Country_Poster_Book%20_final_V2.pdf)).
For **explanation/definition** of the terms used, please see the [**Glossary**](https://ppri.goeg.at/ppri-glossary).

The **aim** of the country poster is to picture the pharmaceutical pricing and reimbursement process of your country on one page. Complex structures should be shown in simple graphs.